Astaxanthin; a Promising Protector Against Gentamicin-Induced Nephrotoxicity in Rats

Title:Astaxanthin; a Promising Protector Against Gentamicin-Induced Nephrotoxicity in Rats

Volume: 17 Issue: 13

Author(s): Yasser O. Mosaad, Naglaa Abd El Khalik Gobba and Mohammed A. Hussein

Affiliation:

Keywords: Nephrotoxicity, gentamicin, astaxanthin, oxidative stress biomarkers and antioxidant.

Abstract: Gentamicin is an aminoglycoside antibiotic widely used against infections caused by Gram-negative microorganisms. Nephrotoxicity is the main limitation to its therapeutic use. The objective of this study was to evaluate the potential protective effect of astaxanthin on the renal damage generated by gentamicin in rats, in an attempt to understand its mechanism of action, which may pave the way for possible therapeutic applications. The daily oral administration of the astaxanthin at a concentration of 50 mg/kg for 15 days to gentamicin (80 mg/kg.b.w) treated rats showed a significant decrease (p<0.05) in plasma creatinine, urea, TNF-α as well as plasma and renal MDA and HP. The treatment also resulted in a significant increase in hemoglobin, plasma sodium, potassium and TAS as well as renal total protein, GSH, Pr-SHs, G6PD, SOD, GPx, CAT and GR levels. The histological examinations of renal tissues in this study revealed damage and glomerular infiltration in gentamicin treated rats. The presented data suggest that astaxanthin has a significant prophylactic action against gentamicin-induced nephrotoxicity in rats. The effect was more pronounced in case of astaxanthin pre-treatment compared with administration of astaxanthin post-treatment. Taken together, astaxanthin has a potential as a protective and therapeutic agent for nephrotoxicity and deserves clinical trial in the near future as an adjuvant therapy in patients treated with gentamicin.

Cite this article as:

Mosaad O. Yasser, Gobba Abd El Khalik Naglaa and Hussein A. Mohammed, Astaxanthin; a Promising Protector Against Gentamicin-Induced Nephrotoxicity in Rats, Current Pharmaceutical Biotechnology 2016; 17 (13) . https://dx.doi.org/10.2174/1389201017666160922110740